SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG

5Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Nearly 50% of prostate cancers harbor gene fusions that lead to overexpression of the transcription factor ERG, while a mutually exclusive 10% of prostate cancers harbor recurrent mutations in the gene encoding the E3 ubiquitin ligase SPOP. Recent reports suggest that SPOP acts as a ubiquitin ligase for ERG and propose that ERG stabilization is the oncogenic effector of SPOP mutation. Here, we used human prostate cancer samples and showed that the vast majority of human SPOP-mutant cancers do not express ERG. Comparison of SPOP-mutant and ERG-fusion organoid models showed evidence of divergent, rather than common, transcriptional programs. Furthermore, expression of prostate cancer–associated SPOP mutations in genetically engineered mouse models of SPOP-mutant prostate cancer did not result in the expression of ERG protein in histologically normal prostate glands, high-grade prostatic intraepithelial neoplasia, invasive adenocarcinoma, or prostate organoids. In summary, we found no evidence that ERG is an effector of SPOP mutation in human prostate cancer or mouse models.

Cite

CITATION STYLE

APA

Shoag, J., Liu, D., Blattner, M., Sboner, A., Park, K., Deonarine, L., … Barbieri, C. E. (2018). SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. Journal of Clinical Investigation, 128(1), 381–386. https://doi.org/10.1172/JCI96551

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free